[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648525":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":24,"locations":30,"responsibleParty":44,"collaborators":47,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":23,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":33,"whyStopped":23,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Sechenov University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Rezūm therapy","EXPERIMENTAL","Convective water vapor thermal ablation for benign prostatic hyperplasia",[13],"Procedure: Rezūm",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Rezūm","Rezūm therapy is performed transurethrally by specialists at the study centers in accordance with established clinical practice. The type of anesthesia, the number and location of water vapor injections, treatment of the median lobe, characteristics of the indwelling catheter, and duration of catheterization were determined by the attending physician.",[9],[21,22],"convective water vapor thermal ablation","minimally invasive treatment",null,[25],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Vladislav Petov","CONTACT","+7 925 351 75 49","pettow@mail.ru",[31],{"facility":32,"status":33,"city":34,"state":23,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":23},"Institute for Urology and Reproductive Health, Sechenov University","RECRUITING","Moscow","119435","Russia","RU",{"type":39,"coordinates":40},"Point",[41,42],37.61781,55.75204,{"lat":42,"lon":41},{"type":45,"investigatorFullName":26,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Assosiate Professor, urologist",[48,51,53,55,57,59,61,63,65,67,69,71,73,75],{"name":49,"class":50},"Russian University of Medicine","UNKNOWN",{"name":52,"class":50},"N. I. Pirogov Clinic of High Medical Technologies",{"name":54,"class":50},"UGMK-Zdorovie Medical Center",{"name":56,"class":50},"SM-Clinic Multidisciplinary Medical Holding",{"name":58,"class":50},"MEDSI Group of Companies",{"name":60,"class":50},"URO-PRO Clinic",{"name":62,"class":50},"Avicenna Clinical Hospital",{"name":64,"class":50},"Neftyanik Medical and Sanitary Unit",{"name":66,"class":50},"St. Luke's Clinical Hospital",{"name":68,"class":50},"N. A. Semashko Railway Clinical Hospital (\"RZD-Meditsina\")",{"name":70,"class":50},"Liniya Zhizni LLC",{"name":72,"class":50},"S. P. Botkin Moscow Multidisciplinary Scientific and Clinical Center",{"name":74,"class":50},"European Medical Center",{"name":76,"class":50},"RTH (Real Trans Hair) Medical Center","100648525","mister-study-minimally-invasive-steam-therapy---russian-effectiveness-registry-100648525",false,"NCT07723378","MISTER Study: Minimally Invasive Steam Therapy - Russian Effectiveness Registry","MISTER","Inclusion Criteria\n\n* Lower urinary tract symptoms (IPSS ≥8 points; QoL ≥3 points) due to BPH\n* Prostate volume of 30-150 cm³\n* Qmax ≤15 mL\u002Fs; post-void residual urine volume \\\u003C300 mL\n\nNon-Inclusion Criteria\n\n* Prostate cancer\n* Acute infections of the urinary tract, prostate, or scrotal organs\n* Neurogenic lower urinary tract dysfunction\n* Bladder stone(s)\n* Urethral stricture\n* Prior prostate surgery\n\nExclusion Criteria\n\n* Patient refusal to allow use of medical data for scientific analysis\n* Missing or lost data required for analysis","MALE","18 Years","85 Years",{"count":88,"type":89},1400,"ESTIMATED","INTERVENTIONAL",[92],"NA","Rezūm is a minimally invasive procedure that uses water vapor (steam) to treat urinary symptoms caused by an enlarged prostate (benign prostatic hyperplasia, BPH). It has been used in clinical practice since receiving FDA approval in 2015 and is recommended as a treatment option for men with moderate-to-severe urinary symptoms, including those who wish to preserve ejaculatory function. Clinical trials have shown that Rezūm improves urinary symptoms and flow rates, with benefits that last for at least five years, a low reoperation rate, and a low risk of sexual side effects.\n\nDespite this evidence, several important questions remain. It is not well understood which patients are more likely to experience temporary urinary retention after the procedure, need repeat treatment, or develop ejaculatory changes. Standardized criteria for defining overall treatment success are also lacking.\n\nThe MISTER study is a multicenter registry designed to evaluate real-world outcomes of Rezūm therapy in patients treated in the Russian Federation. Using data from a large patient cohort, the study aims to identify factors associated with urinary retention after catheter removal, the need for repeat treatment or return to medication, and changes in ejaculatory function. The study will also develop and test combined criteria for defining treatment success.",[95,96],"Benign Prostate Hypertrophy(BPH)","LUTS(Lower Urinary Tract Symptoms)",[98,99,100,22],"BPH","LUTS","water vapor thermal ablation","2026-07-20",{"date":103,"type":104},"2026-07-23","ACTUAL",{"date":106,"type":89},"2026-08-01",{"date":108,"type":89},"2027-09",{"name":5,"class":6},1]